On December 1, 2022 Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today that new data from its portfolio of blood tests will be presented at the 2022 San Antonio Breast Cancer Symposium, December 6-10 in San Antonio, Texas (Press release, Guardant Health, DEC 1, 2022, View Source [SID1234624665]). The six poster presentations highlight the use of the Guardant360 blood test and the GuardantINFORM real-world evidence dataset to identify critical biomarkers and acquired co-mutations, track associated treatment patterns and clinical outcomes, and monitor molecular response to therapy based on specific breast cancer driver mutations.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We look forward to sharing new data at the San Antonio Breast Cancer Symposium demonstrating the utility of our blood tests to increase the understanding of potential biomarker targets and the mechanisms of molecular response in patients with advanced breast cancer," said Helmy Eltoukhy, Guardant Health co-CEO. "The presentations will show how data from comprehensive genomic profiling tests provide critical insights that can contribute to the development of more effective therapies and improved patient outcomes."
Full List of Guardant Health Presentations
Guardant360
ctDNA molecular response based on breast cancer driver mutations predicts progression in aromatase inhibitor-sensitive first line treatment of oestrogen receptor-positive (ER+) HER2-negative (HER2-) advanced breast cancer (Poster PD17-02)
TRK inhibitor in a patient with metastatic triple negative breast cancer and NTRK fusions identified via cell-free DNA analysis (Poster P5-02-13)
Cell-free DNA detection of GATA3 mutations in metastatic hormone receptor positive breast cancer: a multi-institutional analysis of incidence, co-mutations, and clinical outcomes (Poster P5-02-07)
Co-occurring alterations in PALB2 germline carriers identified by liquid biopsy in patients with advanced breast cancer (Poster P5-03-18)
Characterization of the genomic landscape of breast carcinoma patients with NF1 alterations using comprehensive cell-free tumor DNA next-generation sequencing (Poster P5-05-03)
Guardant360 and GuardantINFORM
Real-world second-line treatment patterns and associated clinical outcomes for 2795 patients with advanced HR+ HER2- breast cancer treated with first-line CDK4/6 inhibitors (Poster P4-01-18)
The full abstracts are available on the officialSABCS 2022website.